Gene · 5300
Papers3,752
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
121 to 140 of 3,752
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Beneficial Effects of PIN1 Inhibition on Diabetes Mellitus: A Concise Review. | Endocr Metab Immune Disord Drug Targets | 2025 | 38693739 | PubTator, text mining | PubMed |
| Novel Role of Pin1-Cis P-Tau-ApoE Axis in the Pathogenesis of Preeclampsia and Its Connection with Dementia. | Biomedicines | 2024 | 39857613 | PubTator, text mining | PubMed |
| Non-canonical Function of Prolyl Hydroxylase Domain 2 in Breast Cancer Cell Growth and Progression: Role of Peptidyl-prolyl Cis-trans Isomerase NIMA-interacting 1. | J Cancer Prev | 2024 | 39790223 | PubTator, text mining | PubMed |
| The mechanisms of Pin1 as targets for cancer therapy. | Front Immunol | 2024 | 39624096 | PubTator, text mining | PubMed |
| Exosome-based strategy against colon cancer using small interfering RNA-loaded vesicles targeting soluble a proliferation-inducing ligand. | World J Stem Cells | 2024 | 39619877 | PubTator, text mining | PubMed |
| Pin1 promotes human CaV2.1 channel polyubiquitination by RNF138: pathophysiological implication for episodic ataxia type 2. | Cell Commun Signal | 2024 | 39609819 | PubTator, text mining | PubMed |
| Correction to: Nanocarrier of Pin1 inhibitor based on supercritical fluid technology inhibits cancer metastasis by blocking multiple signaling pathways. | Regen Biomater | 2024 | 39569075 | PubTator, text mining | PubMed |
| Targeted degradation of Pin1 by protein-destabilizing compounds. | Proc Natl Acad Sci U S A | 2024 | 39531501 | PubTator, text mining | PubMed |
| Expression of carbohydrate-related genes underlying 3,5,6-TPA-induced fruitlet abscission in citrus. | Sci Rep | 2024 | 39489781 | PubTator, text mining | PubMed |
| Untangling the role of tau in sex hormone responsive cancers: lessons learnt from Alzheimer's disease. | Clin Sci (Lond) | 2024 | 39469929 | PubTator, text mining | PubMed |
| Pin1: Advances in pancreatic cancer therapeutic potential and inhibitors research. | Bioorg Chem | 2024 | 39418844 | PubTator, text mining | PubMed |
| Achieving a 35-Plex Tandem Mass Tag Reagent Set through Deuterium Incorporation. | J Proteome Res | 2024 | 39380184 | PubTator, text mining | PubMed |
| Post-Translational Modifications of RNA-Modifying Proteins in Cellular Dynamics and Disease Progression. | Adv Sci (Weinh) | 2024 | 39377984 | PubTator, text mining | PubMed |
| Pin1 WW Domain Ligand Library Synthesized with an Easy Solid-Phase Phosphorylating Reagent. | Biochemistry | 2024 | 39377814 | PubTator, text mining | PubMed |
| Identification of potential new T cell activation molecules: a Bioinformatic Approach. | Sci Rep | 2024 | 39333573 | PubTator, text mining | PubMed |
| Corrigendum to "Pin1 inhibition reverses the acquired resistance of human hepatocellular carcinoma cells to Regorafenib via the Gli1/Snail/E-cadherin pathway" [Cancer Lett. 444 (2019) 82-93]. | Cancer Lett | 2024 | 39333006 | PubTator, text mining | PubMed |
| On the interface of aging, cancer, and neurodegeneration with SIRT6 and L1 retrotransposon protein interaction network. | Ageing Res Rev | 2024 | 39251041 | PubTator, text mining | PubMed |
| PIN1 is a novel interaction partner and a negative upstream regulator of the transcription factor NFIB. | FEBS Lett | 2024 | 39245791 | PubTator, text mining | PubMed |
| PIN1‑silencing mitigates keratinocyte proliferation and the inflammatory response in psoriasis by activating mitochondrial autophagy. | Exp Ther Med | 2024 | 39234585 | PubTator, text mining | PubMed |
| Re-Evaluating PIN1 as a Therapeutic Target in Oncology Using Neutral Inhibitors and PROTACs. | J Med Chem | 2024 | 39229909 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/5300/papers?page=7